Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, Rebecca Bungay, Annie Guerin & Ann Childress. (2023) Symptoms associated with ADHD/treatment-related adverse side effects and their impact on quality of life and work productivity in adults with ADHD. Current Medical Research and Opinion 39:1, pages 149-159.
Read now
Read now
Jadwiga Najib, Ekaterina Didenko, Daria Meleshkina, Kamila Yusupov, Kateryna Maw, Justin Ramnarain & Maliha Tabassum. (2020) Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder. Current Medical Research and Opinion 36:10, pages 1717-1735.
Read now
Read now
Pengfei Cao, Jun Xing, Yin Cao, Qi Cheng, Xiaojing Sun, Qi Kang, Libin Dai, Xianju Zhou & Zixiang Song. (2018) Clinical effects of repetitive transcranial magnetic stimulation combined with atomoxetine in the treatment of attention-deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment 14, pages 3231-3240.
Read now
Read now
Qiang Liu, Hong Zhang, Qingqing Fang & Lili Qin. (2017) Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials. Journal of Clinical and Experimental Neuropsychology 39:9, pages 854-865.
Read now
Read now
Alain Joseph, Martin Cloutier, Annie Guérin, Roy Nitulescu & Vanja Sikirica. (2016) Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine. Patient Preference and Adherence 10, pages 391-405.
Read now
Read now
Articles from other publishers (28)
Amirmohammad Tajik, Shekoufeh Nikfar, Sepideh Elyasi, Omid Rajabi & Mehdi Varmaghani. (2023) Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran. Child and Adolescent Psychiatry and Mental Health 17:1.
Crossref
Crossref
Brenda M. Y. Leung, Priya Srikanth, Lisa Robinette, Alisha M. Bruton, Gabriella Tost, Irene Hatsu, L. Eugene Arnold & Jeanette M. Johnstone. (2023) Micronutrients for ADHD in youth (MADDY) study: comparison of results from RCT and open label extension. European Child & Adolescent Psychiatry.
Crossref
Crossref
José Ramón Gutiérrez-Casares, Javier Quintero, Cristina Segú-Vergés, Pilar Rodríguez Monterde, Tamara Pozo-Rubio, Mireia Coma & Carmen Montoto. (2023) In silico clinical trial evaluating lisdexamfetamine’s and methylphenidate’s mechanism of action computational models in an attention-deficit/hyperactivity disorder virtual patients’ population. Frontiers in Psychiatry 14.
Crossref
Crossref
Cintya Nirvana Dutta, Leonardo Christov-Moore, Hernando Ombao & Pamela K. Douglas. (2022) Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan. Frontiers in Human Neuroscience 16.
Crossref
Crossref
Davide Martino & James LeckmanFrancesco Cardona & Renata Rizzo. 2022. Tourette Syndrome. Tourette Syndrome
447
476
.
Noa Tsujii, Masahide Usami, Noriyuki Naya, Toshinaga Tsuji, Hirokazu Mishima, Junko Horie, Masakazu Fujiwara & Junzo Iida. (2021) Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review. Neurology and Therapy 10:2, pages 499-522.
Crossref
Crossref
Mohammad Haghighi, Mona Doostizadeh, Leila Jahangard, Alireza Soltanian, Mohammad Faryadres, Kenneth M. Dürsteler, Annette Beatrix Brühl, Dena Sadeghi-Bahmani & Serge Brand. (2021) Influence of Lisdexamfetamine Dimesylate on Early Ejaculation—Results from a Double-Blind Randomized Clinical Trial. Healthcare 9:7, pages 859.
Crossref
Crossref
Mariela Mosheva, Nina Dar, Lee Rima Madi, Abraham Weizman & Doron Gothelf. (2020) Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges. International Clinical Psychopharmacology 35:6, pages 300-304.
Crossref
Crossref
Donald E. Greydanus, Kevin W. Cates & Nina Sadigh. (2019) Adverse effects of stimulant medications in children and adolescents: focus on drug abuse. International Journal of Adolescent Medicine and Health 31:4.
Crossref
Crossref
Arthur Caye, James M. Swanson, David Coghill & Luis Augusto Rohde. (2018) Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Molecular Psychiatry 24:3, pages 390-408.
Crossref
Crossref
Matej Stuhec, Petar Lukić & Igor Locatelli. (2018) Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis. Annals of Pharmacotherapy 53:2, pages 121-133.
Crossref
Crossref
Samuele Cortese, Anneka Tomlinson & Andrea Cipriani. (2019) Meta-Review: Network Meta-Analyses in Child and Adolescent Psychiatry. Journal of the American Academy of Child & Adolescent Psychiatry 58:2, pages 167-179.
Crossref
Crossref
Samuele Cortese, Nicoletta Adamo, Cinzia Del Giovane, Christina Mohr-Jensen, Adrian J Hayes, Sara Carucci, Lauren Z Atkinson, Luca Tessari, Tobias Banaschewski, David Coghill, Chris Hollis, Emily Simonoff, Alessandro Zuddas, Corrado Barbui, Marianna Purgato, Hans-Christoph Steinhausen, Farhad Shokraneh, Jun Xia & Andrea Cipriani. (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry 5:9, pages 727-738.
Crossref
Crossref
Matej Stuhec & Igor Locatelli. (2018) Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study. International Journal of Clinical Pharmacy 40:2, pages 341-344.
Crossref
Crossref
Jeffrey H. Newcorn, Peter Nagy, Ann C. Childress, Glen Frick, Brian Yan & Steven Pliszka. (2017) Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. CNS Drugs 31:11, pages 999-1014.
Crossref
Crossref
Ying Li, Jie Gao, Shu He, Yan Zhang & Qiwei Wang. (2016) An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments. Molecular Neurobiology 54:9, pages 6655-6669.
Crossref
Crossref
Alain Joseph, Rajeev Ayyagari, Meng Xie, Sean Cai, Jipan Xie, Michael Huss & Vanja Sikirica. (2017) Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. European Child & Adolescent Psychiatry 26:8, pages 875-897.
Crossref
Crossref
Vania Modesto-Lowe, Victoria Charbonneau & Pantea Farahmand. (2016) Psychotherapy for Adolescents With Attention-Deficit Hyperactivity Disorder: A Pediatrician’s Guide. Clinical Pediatrics 56:7, pages 667-674.
Crossref
Crossref
M. Stuhec & I. Locatelli. (2020) Age-related pharmacotherapy of attention deficit hyperactivity disorder in Slovenia in children and adolescents: A population-based study. European Psychiatry 42, pages 129-133.
Crossref
Crossref
Marissa King & Peter S. Bearman. (2017) Gifts and influence: Conflict of interest policies and prescribing of psychotropic medications in the United States. Social Science & Medicine 172, pages 153-162.
Crossref
Crossref
Josephine Mauskopf, Stephanie R. Earnshaw, Anita Brogan, Sorrel Wolowacz & Thor-Henrik BrodtkorbSorrel Wolowacz, Josephine Mauskopf & Stephanie Earnshaw. 2017. Budget-Impact Analysis of Health Care Interventions. Budget-Impact Analysis of Health Care Interventions
91
101
.
Evelina A. Zimovetz, Stephen M. Beard, Paul Hodgkins, Matthias Bischof, Josephine A. Mauskopf & Juliana Setyawan. (2016) A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate. CNS Drugs 30:10, pages 985-996.
Crossref
Crossref
Ming-Horng Tsai, Jen-Fu Hsu & Yu-Shu Huang. (2016) Sleep Problems in Children with Attention Deficit/Hyperactivity Disorder: Current Status of Knowledge and Appropriate Management. Current Psychiatry Reports 18:8.
Crossref
Crossref
Chris Bushe, Kathleen Day, Victoria Reed, Kristina Karlsdotter, Lovisa Berggren, Ashley Pitcher, Foula Televantou & Virginia Haynes. (2016) A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients. Journal of Psychopharmacology 30:5, pages 444-458.
Crossref
Crossref
. (2016) Pharmacotherapy of ADHD in Slovenia: realities and perspectives. European Child & Adolescent Psychiatry 25:4, pages 455-457.
Crossref
Crossref
Ferrán Catalá-López, Brian Hutton, Amparo Núñez-Beltrán, Alain D Mayhew, Matthew J Page, Manuel Ridao, Aurelio Tobías, Miguel A Catalá, Rafael Tabarés-Seisdedos & David Moher. (2015) The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic review and network meta-analysis of randomized controlled trials. Systematic Reviews 4:1.
Crossref
Crossref
Juliana Setyawan, Hongbo Yang, David Cheng, Xiaopeng Cai, James Signorovitch, Jipan Xie & M. Haim Erder. (2015) Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder. Value in Health 18:6, pages 824-831.
Crossref
Crossref
Matej Stuhec, Barbara Munda, Vesna Svab & Igor Locatelli. (2015) Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: A meta-analysis with focus on bupropion. Journal of Affective Disorders 178, pages 149-159.
Crossref
Crossref